In aerodigestive cancer, the combined treatment with SMO and HDAC inhibitors promotes cell cycle arrest, suppresses SMO and PTCH1 expression, and delays tumor growth in an animal model, prolonging survival more than a single agent alone [53]. This evidence concerns the gene HDAC9 and neoplasm.